About Leuko - www.leuko.com | careers@leuko.com Leuko is an MIT spin-out developing PointCheckTM, the world’s first non-invasive white blood cell monitoring device. White blood cell assessment is a first-line indicator for multiple medically relevant situations, ranging from cancer chemotherapy management to the detection of life-threatening infections worldwide. Leuko is re-imagining the ...
About Leuko Improving quality of life and outcomes for chemotherapy patients and others at risk of severe neutropenia, through the first noninvasive white cell monitor. This is an investigational device. It is not for sale. The claims made on this website have not been evaluated by the FDA or the CE Mark authorities.
“ Leuko puede mejorar la calidad de vida de muchos pacientes a la vez que suponer un ahorro importante de los costes sanitarios ” Regina Revilla, president of ASEBIO the Spanish Bioindustry Association.
Contact Us Email us at contact@leuko.com or fill out this form. We'd love to hear about how we can help.
Leuko Support Haz clic aquí para obtener ayuda en español. For support please call us: US: +1 (857) 209-4216 (standard rates apply) Spain: (TBD) Or complete the following form: NOTE Do not include your personal information e.g. Name, phone number, email address etc. We will reach out to your clinical team with a response.
Important: Health information on Google isn’t medical advice. If you have a medical concern, make sure to contact a healthcare provider. If you think you may have a medical emergency, immediately call your doctor or your local emergency number. Report incorrect information If you find problems with the health information on Google, you can: